Lucerno Dynamics, LLC

Lucerno Dynamics develops, manufactures, and markets the Lara® System, a passive skin sensor platform designed to detect and quantify radiolabeled biomarkers during nuclear medicine procedures. The system identifies radiopharmaceutical extravasations in seconds, evaluates injection impact within minutes, and reduces error frequency over time. Lara provides real-time quality control and assurance for nuclear medicine administrations, supporting patient-specific dosimetry and therapy response monitoring in solid tumors. With over 28,000 monitored administrations, Lucerno addresses a significant clinical gap: approximately 4.5 million extravasations annually occur in U.S. nuclear medicine procedures, with 500,000+ classified as significant. The system requires minimal patient experience impact (20 seconds added) and technologist workflow disruption (1 minute), making it practical for high-volume clinical settings seeking to enhance safety and procedural confidence.